Azalea Therapeutics
Azalea develops enveloped delivery vehicles (EDVs) for targeted in vivo T-cell genome engineering. Its disclosed preclinical approach includes precise TRAC-locus CAR insertion. This combines delivery and site-specific integration; human therapeutic benefit has not been established.
Corporate information
- Company entity
- Azalea Therapeutics
- Headquarters / principal office
- Berkeley, California, USAOffice location disclosed on the corporate website; a sole legal or global headquarters is not inferred. ↗
- Founded
- 2023 ↗
- Ownership / capital status
- PrivatePrivately financed; seed and Series A combined ↗
- Official corporate reference
- https://azaleatx.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2025-11-04 · Seed and Series A combined · US$82 million combined ↗
Company homepage dates the launch announcement November 4, 2025; UCSF republished it November 5. Aggregate seed plus Series A is not assigned to a single round; launch date is not founding date.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Azalea develops enveloped delivery vehicles (EDVs) for targeted in vivo T-cell genome engineering. Its disclosed preclinical approach includes precise TRAC-locus CAR insertion. This combines delivery and site-specific integration; human therapeutic benefit has not been established.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Official company contact / corporate location disclosure
- Azalea Therapeutics — supporting primary disclosure
- Founding / incorporation disclosure — scope stated in field